Extrarenal Manifestations of Autosomal Dominant Polycystic Kidney Disease: Polycystic Liver Disease

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-1-4939-7784-0_10
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Outcomes and Durability of Hepatic Reduction after Combined Partial Hepatectomy and Cyst Fenestration for Massive Polycystic Liver Disease.

  2016cited by this paper
• Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.

  2016cited by this paper
• Combined liver–kidney transplantation for polycystic liver and kidney disease: analysis from the United Network for Organ Sharing dataset

  2016cited by this paper
• Ursodeoxycholic Acid for Treatment of Enlarged Polycystic Liver

  2016cited by this paper
• Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.

  2016cited by this paper
• Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

  2015cited by this paper
• [Infectious complications in autosomal dominant polycystic kidney disease].

  2015cited by this paper
• Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

  2015cited by this paper
• Glycosylation-directed quality control of protein folding

  2015cited by this paper
• Liver involvement in early autosomal-dominant polycystic kidney disease.

  2015cited by this paper
• Complications infectieuses associées à la polykystose rénale autosomique dominante

  2015cited by this paper
• Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.

  2015cited by this paper
• Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.

  2015cited by this paper
• Whole-exome sequencing reveals LRP5 mutations and canonical Wnt signaling associated with hepatic cystogenesis

  2014cited by this paper
• HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.

  2014cited by this paper
• Polycystic liver disease presenting as pruritus

  2014cited by this paper
• Renal transplantation in autosomal dominant polycystic kidney disease

  2014cited by this paper
• Polycystic liver diseases: advanced insights into the molecular mechanisms

  2014cited by this paper
• Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.

  2013cited by this paper
• Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data

  2013cited by this paper
• Diagnosis and management of polycystic liver disease

  2013cited by this paper
• Treatment of symptomatic polycystic liver disease: transcatheter super-selective hepatic arterial embolization using a mixture of NBCA and iodized oil

  2013cited by this paper
• FDG PET/CT repeatedly demonstrated hepatic cyst infection in a patient with autosomal dominant polycystic kidney disease.

  2013cited by this paper
• The Zebrafish as a Model to Study Polycystic Liver Disease

  2013cited by this paper
• Congenital Hepatic Fibrosis and Portal Hypertension in Autosomal Dominant Polycystic Kidney Disease

  2012cited by this paper
• Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.

  2012cited by this paper
• Complications arising in simple and polycystic liver cysts.

  2012cited by this paper
• The long‐term outcome of patients with polycystic liver disease treated with lanreotide

  2012cited by this paper
• Analysis of baseline parameters in the HALT polycystic kidney disease trials.

  2012cited by this paper
• Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities.

  2012cited by this paper
• Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

  2012cited by this paper
• Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases

  2011cited by this paper
• Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease.

  2011cited by this paper
• Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study

  2011cited by this paper
• A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation

  2011cited by this paper
• Carbohydrate antigen 19-9 as a diagnostic marker for hepatic cyst infection in autosomal dominant polycystic kidney disease.

  2010cited by this paper
• Extended Liver Resection for Polycystic Liver Disease Can Challenge Liver Transplantation

  2010cited by this paper
• Medical and surgical treatment options for polycystic liver disease 1

  2010cited by this paper
• Mammalian target of rapamycin regulates vascular endothelial growth factor–dependent liver cyst growth in polycystin‐2–defective mice

  2010cited by this paper
• Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.

  2010cited by this paper
• Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

  2010cited by this paper
• Congenital Hepatic Fibrosis in a Child with Autosomal Dominant Polycystic Kidney Disease

  2010cited by this paper
• Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.

  2010cited by this paper
• Extrarenal manifestations of autosomal dominant polycystic kidney disease.

  2010cited by this paper
• Cyst infections in patients with autosomal dominant polycystic kidney disease.

  2009cited by this paper
• Polycystic liver disease and liver transplantation: single-institution experience.

  2009cited by this paper
• Transcatheter Arterial Embolization Therapy for a Massive Polycystic Liver in Autosomal Dominant Polycystic Kidney Disease Patients

  2009cited by this paper
• Polycystic Liver Disease: A Critical Appraisal of Hepatic Resection, Cyst Fenestration, and Liver Transplantation

  2009cited by this paper
• Autosomal dominant polycystic kidney disease: the last 3 years.

  2009cited by this paper
• Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

  2009cited by this paper
• Laparoscopic Fenestration of Liver Cysts in Polycystic Liver Disease Results in a Median Volume Reduction of 12.5%

  2008cited by this paper
• Sirolimus reduces polycystic liver volume in ADPKD patients.

  2008cited by this paper
• Polycystic liver and kidney disease: post‐transplant kidney function in patients receiving pre‐emptive kidney transplantation

  2008cited by this paper
• Deficiency of FLCN in Mouse Kidney Led to Development of Polycystic Kidneys and Renal Neoplasia

  2008cited by this paper
• Liver transplantation in polycystic liver disease: A relevant treatment modality for adults?

  2008cited by this paper
• Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK)

  2008cited by this paper
• Living donor liver transplantation in polycystic liver disease

  2008cited by this paper
• Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease

  2007cited by this paper
• Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

  2007cited by this paper
• Inferior Vena Cava Stenting: A Safe and Effective Treatment for Intractable Ascites in Patients with Polycystic Liver Disease

  2007cited by this paper
• Surgical management of polycystic liver disease.

  2007cited by this paper
• Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease.

  2007cited by this paper
• Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases

  2006cited by this paper
• Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease

  2006cited by this paper
• Outcome and quality of life in patients with polycystic liver disease after liver or combined liver‐kidney transplantation

  2006cited by this paper
• Liver and Kidney Transplantation for Polycystic Liver and Kidney-Renal Function and Outcome

  2006cited by this paper
• Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.

  2005cited by this paper
• Polycystic Liver Disease: Experience at a Teaching Hospital

  2005cited by this paper
• Molecular Pathogenesis of Genetic and Inherited Diseases Biliary Dysgenesis in the PCK Rat , an Orthologous Model of Autosomal Recessive Polycystic Kidney Disease

  2004cited by this paper
• Mutations in SEC63 cause autosomal dominant polycystic liver disease

  2004cited by this paper
• Intravascular embolization therapy in a patient with an enlarged polycystic liver.

  2004cited by this paper
• Polycystic disease of the liver

  2004cited by this paper
• Results of combined and sequential liver‐kidney transplantation

  2003cited by this paper
• Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease.

  2003cited by this paper
• The prevalence of simple renal and hepatic cysts detected by spiral computed tomography.

  2003cited by this paper
• Single-session alcohol sclerotherapy in symptomatic benign hepatic cysts performed with a time of exposure to alcohol of 10 min: initial results

  2003cited by this paper
• Liver transplantation for polycystic liver disease--indications and outcome.

  2003cited by this paper
• Intrahepatic cholangiocarcinoma arising in autosomal dominant polycystic kidney disease

  2002cited by this paper
• [Budd-Chiari syndrome in polycystic kidney disease].

  2001cited by this paper
• Liver transplantation for polycystic liver disease

  2001cited by this paper
• Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1.

  2000cited by this paper
• Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma.

  2000cited by this paper
• Liver transplantation for adult polycystic liver disease

  1998cited by this paper
• Acute abdomen in a haemodialysed patient with polycystic kidney disease--rupture of a massive liver cyst.

  1998cited by this paper
• In-111 WBC scan localizes infected hepatic cysts and confirms their complete resection in adult polycystic kidney disease.

  1998cited by this paper
• Pregnancy in a patient with autosomal-dominant polycystic kidney disease and congenital hepatic fibrosis.

  1998cited by this paper
• Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease

  1997cited by this paper
• Distribution and developmentally regulated expression of murine polycystin.

  1997cited by this paper
• Polycystin: in vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein.

  1997cited by this paper
• Autosomal dominant polycystic kidney disease with anticipation and Caroli's disease associated with a PKD1 mutation. Rapid communication.

  1997cited by this paper
• Adult polycystic liver disease: is fenestration the most adequate operation for long-term management?

  1997cited by this paper
• Expression of polycystin in mouse metanephros and extra-metanephric tissues.

  1997cited by this paper
• Liver transplantation in patients with polycystic liver disease.

  1997cited by this paper
• Persistent Fever in a Patient with Polycystic Kidney and Liver Diseases and Bilateral Hip Prostheses

  1996cited by this paper
• Liver transplantation for adult polycystic liver disease.

  1996cited by this paper
• Immunolocalization of polycystin in human tissues and cultured cells.

  1996cited by this paper
• Hepatic venous outflow obstruction in patients with polycystic liver disease: pathogenesis and treatment.

  1995cited by this paper
• Symptomatic hepatic cysts: percutaneous drainage and sclerosis.

  1994cited by this paper
• Alcohol sclerosis for polycystic liver disease and obstructive jaundice: use of a nasobiliary catheter.

  1994cited by this paper
• Hepatic venous outflow obstruction in autosomal dominant polycystic kidney disease.

  1994cited by this paper

• Severe polycystic liver disease: An unsual cause of chronic Budd-Chiari Syndrome

  2022cites this paper
• Polyvisceral polycystic disease: a case study and review

  2021cites this paper
• Anatomical, histomorphological and molecular classification of cholangiocarcinoma

  2019cites this paper
• Tiny Non-coding RNAs in Body Fluids, Possible Biomarkers for Autosomal Dominant Polycystic Kidney Disease.

  2019cites this paper